Management of Advanced Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer and Brain Metastases: ASCO Guideline Update Q and A

Abstract

ASCO recently published an updated guideline for the management of advanced human epidermal growth factor receptor 2 (HER2)–positive breast cancer and brain metastases, 1 along with a companion guideline on systemic therapy for patients with HER2-positive advanced breast cancer. 2 Recent data on local therapy and systemic therapy advances for patients with HER2-positive advanced breast cancer and brain metastases drove updates to the guideline recommendations, previously updated in 2018. 3 In this article, guideline authors address the nuances of selecting the appropriate treatment and surveillance regimens for these patients ( Fig 1 ).